These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9164195)

  • 1. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 May; 15(5):1853-7. PubMed ID: 9164195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
    J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
    Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
    Sengeløv L; Kamby C; Lund B; Engelholm SA
    J Clin Oncol; 1998 Oct; 16(10):3392-7. PubMed ID: 9779718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in the management of advanced or metastatic urothelial tract cancer.
    Logothetis C; Millikan R
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):107-11. PubMed ID: 12108893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
    de Wit R; Kruit WH; Stoter G; de Boer M; Kerger J; Verweij J
    Br J Cancer; 1998 Nov; 78(10):1342-5. PubMed ID: 9823976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
    Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
    J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Bakoyannis C; Georgoulias V; Papadimitriou C; Moulopoulos LA; Deliveliotis C; Karayannis A; Varkarakis I; Aravantinos G; Zervas A; Pantazopoulos D; Fountzilas G; Bamias A; Kyriakakis Z; Anagnostopoulos A; Giannopoulos A; Kosmidis P
    Ann Oncol; 1999 Nov; 10(11):1385-8. PubMed ID: 10631471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
    Krege S; Rembrink V; Börgermann C; Otto T; Rübben H
    J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
    Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
    J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel.
    Dimopoulos MA; Deliveliotis C; Moulopoulos LA; Papadimitriou C; Mitropoulos D; Anagnostopoulos A; Athanassiades P; Dimopoulos C
    Urology; 1998 Jul; 52(1):56-60. PubMed ID: 9671871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
    Belani CP; Einzig A; Bonomi P; Dobbs T; Capozzoli MJ; Earhart R; Cohen LJ; Luketich JD
    Ann Oncol; 2000 Jun; 11(6):673-8. PubMed ID: 10942054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
    Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
    J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
    Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
    J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
    Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.